Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Hair follicles cannot be desensitized to DHT like allergies; treatments focus on reducing DHT levels or blocking its effects using methods like finasteride, GT20029, or PROTACs. Topical treatments like ceterizine and BPA application are also mentioned.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

Breezula/Winlevi's potential use for hair loss is discussed, with concerns about its effectiveness compared to Breezula's higher concentration. Users express interest in a topical treatment with minimal side effects, noting that Breezula's efficacy may decline after six months.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.

Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

The conversation discusses the potential benefits of topical caffeine for Androgenetic Alopecia (APA) and female pattern hair loss. While some studies suggest positive results, there's no reliable scientific evidence to strongly recommend caffeine compounds for hair regrowth.

Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.

The conversation is about finding clascoterone 5% or other effective anti-androgens for hair loss in the UK, with openness to purchasing from outside the UK. A suggestion was made to visit Dublin, where research on the treatment is ongoing.

Caffeine might raise stress hormones, potentially worsening hair loss. Telogen effluvium is often misattributed to minor stressors rather than significant life events.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

The user is considering increasing their dutasteride dose and trying clascoterone or RU58841 for hair loss stabilization. They have used finasteride, minoxidil, and dutasteride, with some success but recent setbacks.

Caffeine may promote hair growth and potentially inhibit 5-α-reductase activity in hair follicles, but its effectiveness and systemic impact remain unclear. Users discuss using topical caffeine solutions, with some experiencing no side effects compared to finasteride.

Rotenone, a natural plant extract, may promote hair growth by increasing LDH activity and blocking MPC in the scalp, but it carries risks due to its toxicity. The suggested formulation includes Barbasco extract, DMSO, propylene glycol or PEG-400, ethanol, and a carrier oil.

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

Caffeine shampoo may cause increased hair fall initially, but its effectiveness in reducing hair loss is debated. Some users suggest ketoconazole shampoo as a better alternative for healthier scalp and reduced hair shedding.

The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

The conversation discusses the use of coenzyme Q10 as a potential aid for androgenetic alopecia, alongside dutasteride. The user is seeking feedback on whether coenzyme Q10 improves or worsens hair condition.

CB-03-01, also known as Breezula, is being considered as an alternative to DHT blockers for hair loss. Users are discussing its effectiveness, potential regrowth, side effects like scalp irritation, and hormonal impacts.

The conversation is about using coenzyme Q10 for hair loss alongside dutasteride. The effectiveness of coenzyme Q10 for treating androgenetic alopecia is questioned due to a lack of evidence.

The conversation is about a user obtaining a compounded treatment for hair loss, including 0.1% latanoprost, 0.2% melatonin, and 1% cetirizine. The user also uses 2.5 mg dutasteride, 5 mg minoxidil, and RU58841 daily, and is at Norwood 2.

A promising stem cell treatment for hair loss using adipose-derived stem cell conditioned medium is discussed. Users express interest in the treatment's cost and effectiveness, noting impressive results from a 2015 study.

Carnosic acid in rosemary extract may enhance skin repair and promote hair follicle regeneration. It could be used alone or with verteporfin for scarless healing after dermal wounding.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

The conversation discusses the importance of scalp skin barrier health in hair follicle cycling, suggesting treatments like ceramides or niacinamide to support hair growth. It also mentions the use of finasteride for hair loss.

Using PP405 and Clascoterone after a hair transplant may not cause issues if the transplant didn't achieve native density, but could lead to competition for blood supply if it did. Some users suggest waiting for these drugs to be available, as they might not significantly impact blood supply or regrowth.